Eisai Experts Define Meaningful Benefits for Alzheimer's Disease (AD) Patients & Care Partners Along the Clinical Journey at AAIC 2022
Watch to learn about benefits across the clinical journey that can practically help healthcare teams move towards slowing disease progression and improving disease management..
The demonstration of meaningful benefits across Alzheimer’s disease (AD) patients, clinicians, and care partners is undeniably critical and varies across different stages of the clinical care journey. Thus, identifying meaningful benefits is imperative to move towards slowing disease progression or disease management.
Credit: Eisai Inc.
Presented at the 2022 Alzheimer’s Association International Conference (AAIC), four leading experts describe AD patient perspectives in the contexts of timely diagnostic journey, biomarker utility in AD diagnosis and management, and provide guidance to healthcare professionals that may be helpful when communicating the most relevant outcomes to AD patients and care partners.
1. Dr. van Dyck: Introduction to the Alzheimer's Landscape
Identifying meaningful benefits for diagnosis and management requires a multidimensional and comprehensive approach to patient care. Here, Dr. Christopher van Dyck provides an introduction and overview of the landscape of an Alzheimer’s disease patient through the course of healthy aging, diagnosis, and clinical care pathway.
2. Dr. Boustani: Challenges with Early Detection of AD
Many individuals with mild cognitive impairment are not identified until symptoms emerge. Here, Dr. Malaz Boustani discusses the challenges related to early detection of AD seen in the geriatric/primary care setting, as well as potential solutions to overcome such challenges.
3. Dr. Jessen: Biomarkers and the AD Continuum
The AT(N) framework places individuals on the Alzheimer’s disease continuum based on core AD biomarkers: amyloid-β(A), tau (T) and neurodegeneration (N). Here, Dr. Frank Jessen explains biomarkers, risk of dementia in relation to AT(N) profiles, and how to effectively communicate the relevance of biomarkers to patients.
4. Dr. Cohen: Setting Expectations for Outcomes
Assessment tools and outcome measures used often differ in clinical trials and clinical practice. Here, Dr. Sharon Cohen discusses which outcomes matter most to patients, how to manage patient expectations, and highlights the importance of developing mutual understanding and expectation of disease attenuation between clinicians and patients.
Our four decades of AD research helped pave the way for scientific breakthroughs and advances that are shaping the future of neurology. Paired with our long-term vision and commitment to our human health care (hhc) mission, we use deep human biology and genetic evidence with the goal of providing the right intervention, for the right person, at the right time.
Eisai’s rich neurology pipeline builds upon our pioneering history. From the research and development of a symptomatic breakthrough treatment in the 1980s, to our continued development of anti-amyloid-beta and anti-tau antibodies, we stand at the forefront of dementia research.